迪安诊断(300244) - 2025 Q1 - 季度财报

Financial Performance - In Q1 2025, the company reported revenue of CNY 2.37 billion, a decrease of 20.45% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of CNY 21 million, representing a decline of 190.66% year-on-year[4] - The net profit after deducting non-recurring gains and losses was a loss of CNY 26 million, down 211.77% from the previous year[4] - Total operating revenue for the current period is ¥2,365,125,686.41, a decrease of approximately 20.4% from ¥2,973,005,617.76 in the previous period[18] - Net profit for the current period is ¥4,172,276.06, a significant decline of 94.5% compared to ¥76,393,132.63 in the previous period[19] - The company reported a loss attributable to the parent company of ¥21,005,565.65, compared to a profit of ¥23,170,466.54 in the previous period[19] Cash Flow and Liquidity - The company's cash flow from operating activities improved by 36.61%, amounting to a net outflow of CNY 169 million[7] - Cash flow from operating activities showed a net outflow of ¥169,216,515.68, an improvement from a net outflow of ¥266,945,833.56 in the previous period[21] - The company's cash and cash equivalents decreased to CNY 1,303,520,270.00 from CNY 1,830,317,273.55, reflecting a decline of approximately 29%[13] - Cash and cash equivalents at the end of the period decreased to ¥1,281,147,970.80 from ¥2,256,555,242.50 in the previous period[22] - Investment activities resulted in a net cash outflow of ¥79,047,843.36, compared to a larger outflow of ¥459,639,091.92 in the previous period[21] - Financing activities generated a net cash outflow of ¥260,482,227.22, contrasting with a net inflow of ¥35,668,498.90 in the previous period[21] Assets and Liabilities - The total assets at the end of the reporting period were CNY 15.21 billion, a decrease of 3.65% from the end of the previous year[4] - The total assets of the company as of March 31, 2025, amounted to CNY 15,210,416,052.74, a decrease from CNY 15,785,983,734.55 in the previous period[13] - The total liabilities decreased to CNY 6,469,877,512.38 from CNY 7,018,794,162.32, representing a reduction of approximately 7.8%[15] - The company's total equity as of the end of the reporting period was CNY 8,740,538,540.36, down from CNY 8,767,189,572.23, a decrease of about 0.3%[15] - The company's total current assets decreased to CNY 11,358,243,612.83 from CNY 11,902,542,869.23, a decrease of approximately 4.6%[13] Shareholder Information - The company had a total of 54,498 common shareholders at the end of the reporting period[9] - The company held 13,880,000 shares in its repurchase account, accounting for 2.22% of the total share capital at the end of the reporting period[10] Operational Efficiency and Strategy - The company's cash flow from operating activities improved by 36.61%, amounting to a net outflow of CNY 169 million[7] - The gross profit margin increased by approximately 1% year-on-year, indicating improved operational efficiency[8] - The company plans to focus on innovation and operational efficiency, emphasizing a "digital + automation + AI" business model[8] - The company aims to explore new healthcare businesses, including health management, to adapt to complex market conditions[8] Investment and Debt - The investment loss increased by 239.36% due to losses from accounts receivable debt restructuring in subsidiaries[7] - Accounts receivable increased slightly to CNY 7,271,041,135.60 from CNY 7,258,897,680.33, indicating a marginal growth of about 0.17%[13] - Long-term investments increased slightly to CNY 961,108,507.05 from CNY 959,901,876.31, showing a growth of about 0.13%[14] - Short-term borrowings rose to CNY 691,598,078.82 from CNY 616,218,694.22, an increase of approximately 12.2%[15] - The company experienced a credit impairment loss of ¥100,237,182.78, an increase from ¥92,783,263.47 in the previous period[19]